Soliris has been approved in the European Union for expanded use to include the treatment of refractory generalised myasthenia gravis, or gMG, in children and adolescents aged six to 17 years who are anti-acetylcholine receptor antibody-positive, AstraZeneca announced. “This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU,” the company said.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- Is AZN a Buy, Before Earnings?
- Pfizer price target lowered to $42 from $43 at Morgan Stanley
- Pieris Pharmaceuticals announces restructuring, to reduce workforce by 70%
- AstraZeneca (NASDAQ:AZN) and Sanofi Secure FDA Green Light
- Sanofi, AstraZeneca confirm FDA approves Beyfortus for RSV disease in infants